Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 181-186

  Polachek, Ari ^a,c   Korobko, Uri ^a,c   Mader Balakirski, Noa ^a,c   Arad, Uri ^a,c   Levartovsky, David ^a,c   Kaufman, Ilana ^a,c   Anouk, Marina ^a,c   Litinsky, Ira ^a,c   Wigler, Irina ^a,c   Mendelson, Ella ^b,c   Paran, Daphna ^a,c   Matz, Hagit ^a,c   Caspi, Dan ^a,c   Mandelboim, Michal ^b,c   Elkayam, Ori ^a,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Influenza vaccine psoriasis arthritis

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLUENZA VACCINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS ANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SEASONAL INFLUENZA; SEX DIFFERENCE; SINGLE DRUG DOSE; ARTHRITIS, PSORIATIC; BLOOD; CASE CONTROL STUDY; IMMUNIZATION; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA, HUMAN; MIDDLE AGED; SEASON; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PSORIASIS; SEASONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929939618     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. BAUTISTA E, CHOTPITAYASUNONDH T, GAO Z et al.: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-19.
2. RICE TW, RUBINSON L, UYEKI TM et al.: Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40: 1487-98.
3. NIN N, SOTO L, HURTADO J et al.: Clinical characteristics and outcomes of patients with 2009 influenza A(H1N1) virus infection with respiratory failure requiring mechanical ventilation. J Crit Care 2011; 26: 186-92.
4. VIASUS D, PANO-PARDO JR, PACHON J et al.: Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine 2011; 90: 328-36.
5. BLUMENTALS WA, ARREGLADO A, NAPAL-KOV P et al.: Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Dis 2012; 13: 158.
6. BOSCH X, GUILABERT A, PALLARES L et al.: Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006; 15: 584-9.
7. DORAN MF, CROWSON CS, POND GR et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
8. ILIOPOULOS AG, TSOKOS GC: Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25: 318-36.
9. MARIETTE X, GOTTENBERG JE, RAVAUD P et al.: Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
10. General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 2011; 60: 1-64.: KROGER AT, ATKINSON WL, MARCUSE EK, PICKERING LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-48.
11. van ASSEN S, AGMON-LEVIN N, ELKAYAM O et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
12. ABU-SHAKRA M: Safety of vaccination of patients with systemic lupus erythematosus. Lupus 2009; 18: 1205-8.
13. ELKAYAM O, AMIR S, MENDELSON E et al.: Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63: 1062-7.
14. ELKAYAM O, BASHKIN A, MANDELBOIM M et al.: The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-7.
15. FOMIN I, CASPI D, LEVY V et al.: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-4.
16. BURMESTER GR, MEASE P, DIJKMANS BA et al.: Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
17. DOMMASCH ED, ABUABARAb K, SHIN DB et al.: The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermaol 2011; 64: 1035-50.
18. SAAD AA, ASHCROFT DM, WATSON KD et al.: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 697-705.
19. WAKKEE M, de VRIES E, van den HAAK P, NIJSTEN T: Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 2011; 65: 1135-44.
20. MEASE PJ, RITCHLIN CT, MARTIN RW et al.: Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31: 1356-61.
21. SAAD CG, BORBA EF, AIKAWA NE et al.: Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011; 70: 1068-73.
22. Committee for proprietary medicinal products (CPMP). Note for guidance on harmonization of requirments for influenza vaccines 1997. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelines/2009/09/WC500003945.pdf.
23. Committee for proprietary medicinal products (CPMP). Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines 2001. CPMP/EPW/1045/01.
24. PALMER DF, COLEMAN MT, DOWDLE WR, SCHILD GC: Advanced laboratory techniques for influenza diagnosis. Washington DC: US Department of Health, Education and Welfare. 1975.
25. KOCA R, ALTINYAZARl HC, NUMANOGLU G, UNALACAK M: Guttate psoriasis-like lesions following BCG vaccination. J Trop Pediatr 2004; 50: 178-9.
26. MACIAS VC, CUNHA D: Psoriasis triggered by tetanus-diphtheria vaccination. Cutan Ocul Toxicol 2013; 32: 164-5.
27. TAKAYAMA K, SATOH T, HAYASHI M, YOKOZEKI H: Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol 2008; 88: 621-2.
28. PATTISON E, HARRISON BJ, GRIFFITHS CE, SILMAN AJ, BRUCE IN: Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008; 67: 672-6.
29. EDER L, LAW T, CHANDRAN V et al.: Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res 2011; 63: 1091-7.
30. CURTIS JR, ARORA T, NARONGROEKNAWIN P et al.: The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 2010; 12: R144.
31. SBIDIAN E, TUBACH F, PASQUET B et al.: Factors associated with 2009 monovalent H1N1 vaccine coverage: a cross sectional study of 1,308 patients with psoriasis in France. Vaccine 2012; 30: 5703-7.
32. SOWDEN E, MITCHELL WS: An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007; 8: 58.